J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade

seekingalpha04-29

Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson (NYSE:JNJ), Roche (OTCQX:RHHBY), and AstraZeneca (NASDAQ:AZN) will allow these companies to reign as the top 3 orphan ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431112067?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1489211062/image_1489211062.jpg","is_english":true,"pubTime":"2024-04-29 01:00","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2431112067","market":"us","top_or_hot":-1,"title":"J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade","media":"seekingalpha","content":"<div>\n<p>Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson (NYSE:JNJ), Roche (OTCQX:RHHBY), and AstraZeneca (NASDAQ:AZN) will allow these companies to reign as the top 3 orphan ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095228-johnson-johnson-roche-astrazeneca-poised-have-highest-orphan-drug-sales-by-end-decade\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>J&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJ&J, Roche, AstraZeneca poised to have highest orphan drug sales by end of decade\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-29 01:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4095228-johnson-johnson-roche-astrazeneca-poised-have-highest-orphan-drug-sales-by-end-decade><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson (NYSE:JNJ), Roche (OTCQX:RHHBY), and AstraZeneca (NASDAQ:AZN) will allow these companies to reign as the top 3 orphan ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095228-johnson-johnson-roche-astrazeneca-poised-have-highest-orphan-drug-sales-by-end-decade\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B1BXHZ80.USD","symbol_name":"Legg Mason ClearBridge - US Appreciation A Acc USD","start_time":0,"source_url":"https://seekingalpha.com/news/4095228-johnson-johnson-roche-astrazeneca-poised-have-highest-orphan-drug-sales-by-end-decade","article_id":"2431112067","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1489211062/image_1489211062.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431112067","pubTimestamp":1714323622,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson (NYSE:JNJ), Roche (OTCQX:RHHBY), and AstraZeneca (NASDAQ:AZN) will allow these companies to reign as the top 3 orphan drugmak","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","BK4550":"红杉资本持仓","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","03165":"华夏欧优股对冲","RHHBY":"罗氏控股","LU1074936037.SGD":"JPMorgan Funds - US Value A (acc) SGD","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","ABBV":"艾伯维公司","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4504":"桥水持仓","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","AZN":"阿斯利康","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","LU1506573853.SGD":"MANULIFE GF GLOBAL EQUITY \"AA\" (SGD) INC","NVS":"诺华","AMGN":"安进","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","JNJ":"强生","LU0882574055.USD":"富达全球健康医疗A ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4592":"伊斯兰概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","BK4567":"ESG概念","LU1261432733.SGD":"Fidelity World A-ACC-SGD","LU1935042991.SGD":"MANULIFE GF GLOBAL MULTI-ASSET DIVERSIFIED INCOME  \"AA\" (SGDHDG) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","SG9999002232.USD":"Allianz Global High Payout USD","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC","BK4566":"资本集团","LU0058720904.USD":"联博国际健康护理基金A","LU0661504455.SGD":"Blackrock Global Equity Income A5 SGD-H","VRTX":"福泰制药","BK4559":"巴菲特持仓","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","BK4568":"美国抗疫概念"},"translate_title":"强生，罗氏，阿斯利康将在十年结束前拥有最高的孤儿药销量","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":1,"VRTX":1,"RHHBY":1,"NVS":1,"JNJ":1,"AMGN":1,"AZN":1,"03165":0.6},"content_text":"Orphan drugs -- medicines to treat rare diseases -- from Johnson & Johnson (NYSE:JNJ), Roche (OTCQX:RHHBY), and AstraZeneca (NASDAQ:AZN) will allow these companies to reign as the top 3 orphan drugmakers, by sales, in 2028. A new report from Evaluate found that Johnson & Johnson will be the top orphan drug pharma, bringing in $30.6B from that class alone. Roche is slated to bring in $16.8B in orphan drug sales, followed closely behind by AstraZeneca at $16.4B. Rounding out the top 5 are Novartis (NVS) at $13.9B and Vertex Pharmaceuticals (NASDAQ:VRTX) at $12.4B.  The report notes that in 2028, Amgen (AMGN) will have replaced AbbVie (ABBV) in the top 10 thanks to the former's acquisition of Horizon Therapeutics which closed in October 2023. That deal gave Amgen Tepezza (teprotumumab) for thyroid eye disease, Krystexxa (pegloticase) for gout, and Uplinza (inebilizumab) for neuromyelitis optica spectrum disorders, in addition to Horizon's pipeline. For background, the FDA says that a rare disease is one that affects less than 200,000 people in the U.S., adding that more than 7,000 such diseases impact 30M people in the country. Evaluate finds that the top 3 orphan drugs in 2028 will be Johnson & Johnson's (JNJ) multiple myeloma therapy Darzalex (daratumumab), Vertex's (VRTX) cystic fibrosis treatment Trikafta (elexacaftor/tezacaftor/ivacaftor), and Roche's (OTCQX:RHHBY) hemophilia A therapy Hemlibra (emicizumab). In 2028, Darzalex is expected to bring in $17B worldwide; Trikafta, $8.8B; and Hemlibra, $6.2B. Rounding out the top 5 are AstraZeneca's (AZN) Ultomiris (ravvulizumab) for paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and several other rare disorders, and J&J's CAR-T immunotherapy Carvykti (ciltacabtagene autoleucel) for multiple myeloma. Ultomiris and Carvykti are projected to bring in, respectively, $5.2B and $4.4B.  While oncology indications currently dominate orphan disease therapies -- and will continue to do so in 2028 -- the pharma commercial intelligence, news, and analysis firm projects that its dominance will ebb slightly towards the end of the decade. Oncology presently accounts for 44% of orphan disease treatments. That figure is expected to fall to 42% in 2028. Disease areas such as central nervous system, musculoskeletal, and immunomodulators are expected to grow, from 9%, 4%, and 4%, respectively, to 11%, 6%, and 7%.  \"Oncology has come off the boil as precision medicines tackling ever-narrower genetic mutations run out of road commercially (druggable 'pan-cancer' mutations are elusive), and as CAR-T therapies continue to face challenging administration logistics,\" Evaluate notes. \"CNS orphan drug sales will more than double between 2023 and 2028, by which time they’ll make up over 10% of orphan sales by value\" Evaluate adds. \"This reflects broader industry interest in this once-neglected area.\" More on orphan/rare disease drugs  As more rare disease therapies launch, their prices are rising Sanofi Expands Rare Disease Focus With Inhibrx's INBRX-101 Acquisition Inozyme: Several Catalysts To Move Rare Disease Pipeline Programs Forward Applied Therapeutics gets extension of FDA review for rare disease drug Disc Medicine: Rare Disease Biotech With Enormous Potential","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431112067"}